论文部分内容阅读
为探索非小细胞肺癌的治疗，对30例病人采用三苯氧胺、异搏定加MFP方案（甲组）化疗，并与CAP方案或IEP方案（乙组）进行比较，初步结果显示：两组总有效率分别为43％（13／30）和26．7％（8／30）；甲组毒副反应轻微，生活质量明显改善，一年生存率提高，统计学处理显示差异显著（P＜0．05）。表明使用三苯氧胺、异搏定加化疗MFP方案冶疗非小细胞肺癌具有临床推广和进一步探讨价值。
To explore the treatment of non-small cell lung cancer, 30 patients were treated with tamoxifen, verapamil plus MFP regimen (group A), and compared with CAP regimen or IEP regimen (group B). The preliminary results showed that: The efficiencies were 43% (13/30) and 26.7% (8/30) respectively; the toxicity of group A was mild, the quality of life was significantly improved, and the one-year survival rate was improved. Statistically, the difference was significant (P<0. 05). It was shown that the use of tamoxifen, verapamil plus chemotherapy MFP regimen for the treatment of non-small cell lung cancer has clinical promotion and further exploration value.